Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Culturelle

Mass-Market LGG Brand (DSM-Firmenich)

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

80 human trials, about 300 studies, >20,000 participants (LGG strain). The written rationale for this grade is still being prepared.

FDA
USP-verified options
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

This is a single-strain product; benefits are indication-specific and do not generalize to all digestive complaints, and the large 2018 gastroenteritis trials found no benefit for acute stomach illness. Some Culturelle lines are USP-verified and others are not, so check the specific product. For generally healthy people LGG is well tolerated, but documented case reports describe LGG bacteremia and sepsis in critically ill, immunocompromised, central-line, or post-transplant patients, so people who are immunocompromised, seriously ill, or pregnant, and anyone considering probiotics for an infant, young child, or during pregnancy, should consult a qualified healthcare provider before use. This entry is informational and is not a treatment protocol.

Culturelle is a mass-market probiotic whose flagship product is built on Lactobacillus rhamnosus GG (LGG), one of the most-studied probiotic strains in the world. The brand is made by i-Health, a division of DSM-Firmenich, and licenses the patented LGG strain from Chr. Hansen, now part of Novonesis. The strain evidence is genuinely deep but indication-specific: it is associated with reduced antibiotic-associated diarrhea, especially in children, while two large, rigorous 2018 NEJM emergency-department trials found it no better than placebo for acute gastroenteritis. Culturelle's brand claims should be read as the maker's positioning; the useful Enel contribution is separating that marketing from the strain's actual, mixed clinical record.

A commodity product hiding the world most-studied strain. Excellent value-for-evidence.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Prevention of antibiotic-associated diarrhea, the strain's best-evidenced use, strongest signal in children
  • General digestive support, as marketed by the maker
  • Adjunct to oral rehydration in acute childhood diarrhea when started early, an indication where the evidence is now mixed and guideline support has weakened

What people get wrong

  • Often saidPremium price means premium probiotics

    ActuallyThe brand is associated with one of the most-studied strains at commodity prices, but price and evidence are decoupled in both directions. i-Health/DSM-Firmenich markets LGG's strong AAD-prevention record; that is the maker's positioning. It does not mean LGG helps every gut complaint, as the negative 2018 gastroenteritis trials show.

  • Often saidLGG is proven to shorten stomach bugs in kids

    ActuallyMixed, not proven. Earlier pooled data (Li et al. 2019, 19 RCTs) associated LGG with roughly 24 fewer hours of diarrhea when given early at high dose, but the two large 2018 NEJM emergency-department trials (Schnadower, 971 children; Freedman, 886 children) found no benefit over placebo, and AGA's 2020 guideline recommends against routine use for acute gastroenteritis.

  • Often saidMore strains beat one strain

    ActuallyDiversity and efficacy are not the same thing. Freedman's 2018 trial tested a multi-strain (L. rhamnosus plus L. helveticus) combination and still found no benefit for acute gastroenteritis. Strain count is not a reliable proxy for whether a product works for a given indication.

  • Often saidA probiotic that survived rigorous trials must be safe for everyone

    ActuallyFor generally healthy people LGG has a long safety record, but documented case reports describe LGG bacteremia and sepsis in critically ill or immunocompromised patients, including central-line and post-transplant cases. Safety is population-specific, not universal.

Who profits, and who pushes back

  • Pharmacists and pediatricians

    Promotes itClinical

    Frequently recommend Culturelle precisely because LGG has strong, specific evidence.

  • DSM-Firmenich

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itParent company

    Markets the LGG strain at mass-market scale; genuine evidence, commodity positioning.

  • American Gastroenterological Association (AGA)

    Pushes backUS professional gastroenterology society, 2020 clinical guideline

    The AGA states that these studies show two particular probiotic supplements containing L. rhamnosus GG are of no benefit for children with acute gastroenteritis, and its 2020 guideline recommends against routine probiotic use for most gastrointestinal conditions, including acute gastroenteritis.

  • David Schnadower and colleagues (PECARN investigators)

    Pushes backLead authors, 2018 NEJM randomized trial of 971 children

    The authors conclude that among preschool children with acute gastroenteritis, those who received a 5-day course of L. rhamnosus GG did not have better outcomes than those who received placebo.

  • ISAPP (Guarner, Cabana, Sanders)

    Pushes backInternational Scientific Association for Probiotics and Prebiotics, defending an early-treatment reading

    ISAPP experts argue the 2018 null results may reflect late initiation, since children were symptomatic for a median of roughly 48 to 53 hours before treatment, close to spontaneous remission, and say the trials should not overturn recommendations to use probiotics early after onset alongside oral rehydration.

Where the research comes from

Most of the published research on this comes from one place. 58% of it is from USA. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
USA58%
Other42%

Research published from: USA, Global.

How we got here

Lactobacillus rhamnosus GG was isolated in 1983 by Sherwood Gorbach and Barry Goldin at Tufts University in Boston; the 'GG' comes from their surnames, and the strain (ATCC 53103) was filed for patent in April 1985. It was one of the first human-origin probiotic strains selected specifically for acid and bile tolerance and adhesion to intestinal cells. Commercialization moved first through Finland, where Valio licensed LGG for its Gefilus dairy line, spreading it across Nordic and European markets before it reached US pharmacy shelves. Culturelle brought the strain into US mass retail in 1998. Ownership then passed through Amerifit Brands (2006), Martek Biosciences (2010), and DSM's acquisition of Martek (2011), leaving the brand under i-Health, a DSM-Firmenich division. In 2020 the species was reclassified as Lacticaseibacillus rhamnosus. Rather than chase strain-count marketing, the brand stayed centered on the single well-studied LGG strain.

  1. 1983Gorbach and Goldin isolate the LGG strain from a healthy human gut at Tufts University, Boston
  2. 1985Patent filed on the strain, later catalogued as ATCC 53103
  3. 1990Valio in Finland licenses LGG for its Gefilus products, seeding European markets years before US retail
  4. 1998Culturelle introduced in the United States as a consumer LGG capsule
  5. 2006Amerifit Brands acquires Culturelle
  6. 2010-2011Martek Biosciences acquires Amerifit; DSM then acquires Martek, placing Culturelle under i-Health
  7. 2015Szajewska and Kolodziej meta-analysis (12 RCTs, 1499 participants) associates LGG with reduced antibiotic-associated diarrhea
  8. 2018Two large NEJM emergency-department RCTs, Schnadower (US) and Freedman (Canada), find LGG no better than placebo for acute pediatric gastroenteritis
  9. 2020Updated Cochrane review and AGA guidance move against routine probiotics for acute pediatric gastroenteritis; species reclassified as Lacticaseibacillus rhamnosus

At a glance

Strain
L. rhamnosus GG
Owner
DSM-Firmenich
Best for
Antibiotic diarrhea
Value
High evidence, low price

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Culturelle. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources